Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with: BRAF: and: NRAS: mutations and systematic review
Disseminated intravascular coagulation is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficult to diagnose in some circumstances, leading to delay in treatment. Herein, we describe the first case of disseminated intravascular coagulation occurring in BRAF and NRAS-mutant metastatic melanoma, and systematically review the literature regarding disseminated intravascular coagulation in melanoma. This review summarizes the reported cases of disseminated intravascular coagu...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program
Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010–August 2013 in Europe, New Zealand and Australia. Of the 331 Named Patient Program patients included, the majority (95.8%) had stage IV disease at dabrafenib initiation and 39.9% had brain metastases (BMs). Dabrafenib was used first line in 67...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Inflammatory side effects of BRAF and MEK inhibitors
The aim of this study was to describe inflammatory side effects in patients treated with BRAF and MEK inhibitors at a single tertiary care institution. This was a retrospective chart review of patients prescribed single-agent or combination BRAF and MEK inhibitors from January 2010 until May 2015. The primary outcome was the presence of inflammatory side effects. Among 124 patients, 56.4% were male, the median age was 59 years, and most (91.1%) were treated for metastatic melanoma. Most patients (74.2%) developed inflammatory side effects, some with multiple occurrences, for a total of 211 occurrences. The overall prevalen...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases
The common adverse effects of immune checkpoint blockade therapy are well recognised. However, neurological adverse effects of checkpoint inhibitor therapy are less widely appreciated, and their clinical management remains challenging. Therefore, we report our experience of managing acute, life-threatening neurological toxicity during immune checkpoint inhibitor therapy. Five male patients with stage IV melanoma underwent anti-programmed cell death protein 1 therapy (monotherapy or combination therapy with anti-cytotoxic T-lymphocyte antigen-4 antibodies) and developed severe neurological symptoms and signs including heada...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma
In conclusion, LMR seems to be associated with OS. Further prospective investigations are needed to confirm these data and introduce peripheral blood cell count in daily clinical use. (Source: Melanoma Research)
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma
In several cancers, tumor progression is associated with the infiltration of tumor-associated macrophages (TAMs). The aim was to evaluate the prognostic significance of expression of CD163 and CD68 (TAMs’ markers) and their correlation with vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression in cutaneous melanoma. Diagnostic tissues from 102 patients of cutaneous melanoma were evaluated by immunohistochemistry for their CD68, CD163, VEGF, and COX-2 expression. Correlations between the proteins were then investigated. Clinicopathological features, overall survival (OS), and progression-free s...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy
Neuroblastoma RAS viral oncogene homolog is a commonly mutated oncogene in melanoma, and therapeutic targeting of neuroblastoma RAS viral oncogene homolog has proven difficult. We characterized the expression and phenotypic functions of five recently discovered splice isoforms of neuroblastoma RAS viral oncogene homolog in melanoma. Canonical neuroblastoma RAS viral oncogene homolog (isoform-1) was expressed to the highest degree and its expression was significantly increased in melanoma metastases compared to primary lesions. Isoform-5 expression in metastases showed a significant, positive correlation with survival and t...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma
Germline mutations of BRCA1 and BRCA2 predispose individuals to a high risk of breast and ovarian cancer, and elevated risk of other cancers, including those of the pancreas and prostate. BRCA2 mutation carriers may have increased risk of uveal melanoma (UM) and cutaneous melanoma (CM), but associations with these cancers in BRCA1 mutation carriers have been mixed. Here, we further assessed whether UM and CM are associated with BRCA1 or BRCA2 by assessing the presence, segregation and reported/predicted pathogenicity of rare germline mutations (variant allele frequency (Source: Melanoma Research)
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging
Alterations in nuclear size and shape are commonly observed in cancers, and its objective evaluation may provide valuable clinical information about the outcome of the disease. Here, we applied the nuclear morphometric analysis in tissues in hematoxylin and eosin-digitized slides of nevi and melanoma, to objectively contribute to the prognostic evaluation of these tumors. To this, we analyzed the nuclear morphometry of 34 melanomas classified according to the TNM stage. Eight cases of melanocytic nevi were used as non-neoplastic tissues to set the non-neoplastic parameters of nuclear morphology. Our samples were set as G1 ...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
Global microRNA profiling of metastatic conjunctival melanoma
This study aimed to investigate the microRNA (miRNA) profile in primary tumors from conjunctival melanoma with and without subsequent metastatic spread along with their coupled distant metastases to identify miRNAs likely to be involved in metastatic progression. This observational study included 13 patients with metastatic conjunctival melanoma (follow-up: 1–39 years) treated at a Danish referral center. Twenty-five patients with nonmetastatic conjunctival melanoma (follow-up: 5–17 years) were included for comparison. Global miRNA profiling was performed with the Affymetrix GeneChip 4.1 microarray. Taqman qPCR arrays ...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Basic Science Source Type: research
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive therapeutic results. Durable responses, however, are only observed in a segment of the patient population and must be offset against severe off-target immune toxicity and high costs. This calls for biomarkers that predict response during ICI treatment. Although many candidate biomarkers exist, as yet, there has been no systematic overview of biomarkers predictive during. Here, we provide a systematic review of the current literature of ICI treatment to establish an overview of candidate predictive biomarkers during ICI trea...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Review Article Source Type: research
Dusky erythema secondary to anti-MEK therapy
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 27, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Exacerbation of skin psoriasis when associating an MEK inhibitor with anti-PD1 immunotherapy for metastatic melanoma
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 27, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 27, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
IRF4 rs12203592*T/T genotype is associated with nodular melanoma
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 27, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
